Survival analysis of ovarian clear cell carcinoma confined to the ovary with or without comprehensive surgical staging

Oncology Reports

Volumn 19, Issue 5, 2008, Pages 1259-1264

  Takano, Masashi ^a   Sasaki, Naoki ^a   Kita, Tsunekazu ^a   Kudoh, Kazuya ^a   Fujii, Kazuyuki ^a   Yoshikawa, Tomoyuki ^a   Kato, Masafumi ^a   Hirata, Junko ^a   Furuya, Kenichi ^a   Tsuda, Hitoshi ^a   Kikuchi, Yoshihiro ^b  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b Ohki Memorial Kikuchi Cancer Clinic for Women   (Japan)

Author keywords

Chemotherapy; Clear cell carcinoma; Lymphadenectomy; Ovarian cancer; Surgical staging

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; IRINOTECAN; PACLITAXEL; PLATINUM COMPLEX;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CONTINUOUS INFUSION; CONTROLLED STUDY; FEMALE; HUMAN; HYSTERECTOMY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PARAAORTIC LYMPH NODE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RELAPSE FREE SURVIVAL; SALPINGOOOPHORECTOMY; SURVIVAL; ADENOCARCINOMA; DISEASE FREE SURVIVAL; METASTASIS; MIDDLE AGED; MORTALITY; OVARY TUMOR; PROPORTIONAL HAZARDS MODEL; REGRESSION ANALYSIS;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; SURVIVAL ANALYSIS;

EID: 47549095072     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.19.5.1259     Document Type: Article

References (42)

1. Bray F, Loos AH, Tognazzo S and La Vecchia C: Ovarian cancer in Europe: Cross-sectional trends in incidence and mortality in 29 countries, 1953-2000. Int J Cancer 113: 977-990, 2005.
2. Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA, Schrag D, Jamison PM, Jemal A, Wu XC, Friedman C, Harlan L, Warren J, Anderson RN and Pickle LW: Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97: 1407-1427, 2005.
3. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL and Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Engl J Med 334: 1-6, 1996.
4. Rose PG, Fusco N, Fluellen L and Rodriguez M: Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian and peritoneal carcinoma. J Clin Oncol 16: 1494-1497, 1999.
5. Dizon DS, Hensley ML, Poynor EA, Sabbatini P, Aghajanian C, Hummer A, Venkatraman E and Spriggs DR: Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. J Clin Oncol 20: 1238-1247, 2002.
6. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A and Trope C: ICON and AGO Collaborators: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in woman with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361: 2099-2106, 2003.
7. Schiller W: Mesonephroma ovarii. Am J Cancer 35: 1-21, 1939.
8. Serov SF, Scully RE and Sobin LH: International histologic classification of tumors. Histologic typing of ovarian tumors. WHO, Geneva, No.9. 1978.
9. Goff BA, Sainz de la Cuesta R, Muntz HG, Fleischhacker D, Ek M, Rice LW, Nikrui N, Tamimi HK, Cain JM, Greer BE and Fuller AF Jr: Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 60: 412-417, 1996.
10. Recio FO, Piver MS, Hempling RE and Driscoll DL: Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy. Cancer 78: 2157-2163, 1996.
11. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I and Taguchi K: Clinical characteristics of clear cell carcinoma of the ovary. Cancer 88: 2584-2589, 2000.
12. Pectasides D, Fountzilas G, Aravantinos G, Kalofonos C, Efstathiou H, Farmakis D, Skarlos D, Pavlidis N, Economopoulos T and Dimopoulos MA: Advanced stage clear- cell epitheliat ovarian cancer: The Hellenic cooperative oncology group experience. Gynecol Oncol 102: 285-291, 2006.
13. Enomoto T, Kuragaki C, Yamasaki M, Sugita N, Otsuki Y, Ikegami H, Matsuzaki N, Yamada T, Wakimoto A and Murata Y, for the Gynecologic Oncology Group of Osaka: Is clear cell carcinoma and mucinous carcinoma of the ovary sensitive to combination chemotherapy with paclitaxel and carboplatin? Proc Am Soc Clin Oncol 22: 447 (abstr 1797), 2003.
14. Ho CM, Huang YJ, Chen TC, Huang SH, Liu FS, Chang Chien CC, Yu MH, Mao TL, Wang TY and Hsieh CY: Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease. Gynecol Oncol 94: 197-203, 2004.
15. Utsunomiya H, Akahira J, Tanno S, Moriya T, Toyoshima M, Niikura H, Ito K, Morimura Y, Watanabe Y and Yaegashi N: Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial. Int J Gynecol Cancer 16: 52-56, 2006.
16. Ho CM, Chien TY, Shih BY and Huang SH: Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage I ovarian clear cell carcinoma. Gynecol Oncol 89: 394-399, 2003.
17. Takano M, Kikuchi Y, Yaegashi N, Kuzuya K, Ueki M, Tsuda H, Suzuki M, Kigawa J, Takeuchi S, Tsuda H, Moriya T and Sugiyama T: Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer 94: 1369-1374, 2006.
18. Adachi S, Ogasawara T, Yamasaki N, Shibahara H, Kanazawa R, Tsuji Y, Takemura T and Koyama K: A pilot study of CPT-11 and cisplatin for ovarian clear cell adenocarcinoma. Jpn J Clin Oncol 29: 434-437, 1999.
19. Kita T, Kikuchi Y, Kudoh K, Takano M, Goto T, Hirata J, Tode T and Nagata I: Exploratory study of effective chemotherapy to clear cell carcinoma of the ovary. Oncol Rep 7: 327-331, 2000.
20. Takano M, Kikuchi Y, Yaegashi N, Suzuki M, Tsuda H, Sagae S, Udagawa Y, Kuzuya K, Kigawa J, Takeuchi S, Tsuda H, Moriya T and Sugiyama T: Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary. Oncol Rep 16: 1301-1306, 2006.
21. Russell P: Surface epithelial-stromal tumors of the ovary. In: Blaustein's Pathology of the Female Genital Tract. Kurman RJ (ed). 4th edition, Springer, New York, pp752-762, 1995.
22. F.I.G.O. Cancer Committee: Staging announcement. Gynecol Oncol 25: 383, 1986.
23. Panici PB, Scambia G, Baiocchi G, Matonti G, Capelli A and Mancuso S: Anatomical study of para-aortic and pelvic lymph nodes in gynecologic malignancies. Obstet Gynecol 79: 498-502, 1992.
24. Pereira A, Magrina JF, Rey V, Cortes M and Magtibay PM: Pelvic and aortic lymph node metastasis in epithelial ovarian cancer. Gynecol Oncol 105: 604-608, 2007.
25. Cass I, Li AJ, Runowicz CD, Fields AL, Goldberg GL, Leuchter RS, Lagasse LD and Karlan BY: Pattern of lymph node metastases in clinically unilateral stage I invasive epithelial ovarian carcinomas. Gynecol Oncol 80: 56-61, 2001.
26. Morice P, Joulie F, Camatte S, Atallah D, Rouzier R, Pautier P, Pomel C, Lhomme C, Duvillard P and Castaigne D: Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. J Am Coll Surg 197: 198-205, 2003.
27. Negishi H, Takeda M, Fujimoto T, Todo Y, Ebina Y, Watari H, Yamamoto R, Minakami H and Sakuragi N: Lymphatic mapping and sentinel node identification as related to the primary sites of lymph node metastasis in early stage ovarian cancer. Gynecol Oncol 94: 161-166, 2004.
28. Takeshima N, Hirai Y, Umayahara K, Fujiwara K, Takizawa K, and Hasumi K: Lymph node metastasis in ovarian cancer: Difference between serous and non-serous primary tumors. Gynecol Oncol 99: 427-431, 2005.
29. Kanazawa K, Suzuki T and Tokashiki M: The validity and significance of substage IIIC by node involvement in epithelial ovarian cancer: impact of nodal metastasis on patient survival. Gynecol Oncol 73: 237-241, 1999.
30. Sakuragi N, Yamada H, Oikawa M, Okuyama K, Fujino T, Sagawa T and Fujimoto S: Prognostic significance of lymph node metastasis and clear cell histology in ovarian carcinoma limited to the pelvis (pT1M0 and p12M0). Gynecol Oncol 79: 251-255, 2000.
31. Onda T, Yoshikawa H, Yasugi T, Mishima M, Nakagawa S, Yamada M, Matsumoto K and Taketani Y: Patients with ovarian carcinoma upstaged to stage III after systematic lymphadenctomy have similar survival to Stage I/II patients and superior survival to other Stage III patients. Cancer 83: 1555-1560, 1998.
32. Cliby WA, Aletti GD, Wilson TO and Podratz KC: Is it justified to classify patients to stage IIIc epithelial ovarian cancer based on nodal involvement only? Gynecol Oncol 103: 797-801, 2006.
33. Chan JK, Munro EG, Cheung MK, Husain A, Teng NN, Berek JS and Osann K: Association of lymphadenectomy and survival in stage I ovarian cancer. Obstet Gynecol 109: 12-19, 2007.
34. Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, Franchi M, Tateo S, Zanetta G, Scarfone G, Giurgea L, Timmers P, Coens C and Pecorelli S: EORTC-ACTION collaborators: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm: Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst 95: 113-125, 2003.
35. Suzuki M, Ohwada M, Saga Y, Kohno, T, Takei Y and Sato I: Micrometastic p53-positive cells in the lymph nodes of early stage ovarian cancer: prognostic significance. Oncology 60: 170-175, 2001.
36. Yabushita H, Shimazu M, Yamada H, Sawaguchi K, Noguchi M, Nakanishi M and Kawai M: Occult lymph node metastasis detected by cytoleratin immunohistochemistry predict recurrence in node-negative endometrial cancer. Gynecol Oncol 80: 139-144, 2001.
37. Maggioni A, Benedetti Panici P, Dell'Anna T, Landoni F, Lissoni A, Pellegrino A, Rossi RS, Chiari S, Campagnutta E, Greggi S, Angioli R, Manci N, Calcagno M, Scambia G, Fossati R, Floriani I, Torri V, Grassi R and Mangioni C: Randomised study of systemic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. Br J Cancer 95: 699-704, 2006.
38. Tsuchiya A, Sakamoto M, Yasuda J, Chuma M, Ohta T, Ohki M, Yasugi T, Taketani Y and Hirohashi S: Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol 163: 2503-2512, 2003.
39. Kato N, Sasou S and Motoyama T: Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary. Mod Pathol 19: 83-89, 2006.
40. Hirasawa A, Saito-Ohara F, Inoue J, Aoki D, Susumu N, Yokoyama T, Nozawa S, Inazawa J and Imoto I: Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPMD1 and APPBP2 as likely amplification targets. Clin Cancer Res 9: 1995-2004, 2003.
41. Kaneuchi M, Sasaki M, Tanaka Y, Shiina H, Yamada H, Yamamoto R, Sakuragi N, Enokida H, Verma M and Dahiya R: WT1 and WT1-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma. Cancer 104: 1924-1930, 2005.
42. Tsuda H, Ito YM, Ohashi Y, Wong KK, Hashiguchi Y, Welch WR, Berkowitz RS, Birrer MJ and Mok SC: Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinoma by cDNA microarray analysis. Clin Cancer Res 11: 6880-6888, 2005.